EP2509424A4 - NOVEL OXADIAZOLE COMPOUNDS - Google Patents

NOVEL OXADIAZOLE COMPOUNDS

Info

Publication number
EP2509424A4
EP2509424A4 EP10836346.6A EP10836346A EP2509424A4 EP 2509424 A4 EP2509424 A4 EP 2509424A4 EP 10836346 A EP10836346 A EP 10836346A EP 2509424 A4 EP2509424 A4 EP 2509424A4
Authority
EP
European Patent Office
Prior art keywords
oxadiazole compounds
novel oxadiazole
novel
compounds
oxadiazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP10836346.6A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP2509424A1 (en
Inventor
Kevin P Cusack
Eric C Breinlinger
Shannon R Fix-Stenzel
Robert H Stoffel
Kevin R Woller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of EP2509424A1 publication Critical patent/EP2509424A1/en
Publication of EP2509424A4 publication Critical patent/EP2509424A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EP10836346.6A 2009-12-08 2010-08-24 NOVEL OXADIAZOLE COMPOUNDS Withdrawn EP2509424A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26767909P 2009-12-08 2009-12-08
PCT/US2010/046424 WO2011071570A1 (en) 2009-12-08 2010-08-24 Novel oxadiazole compounds

Publications (2)

Publication Number Publication Date
EP2509424A1 EP2509424A1 (en) 2012-10-17
EP2509424A4 true EP2509424A4 (en) 2013-09-04

Family

ID=44145850

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10836346.6A Withdrawn EP2509424A4 (en) 2009-12-08 2010-08-24 NOVEL OXADIAZOLE COMPOUNDS

Country Status (9)

Country Link
EP (1) EP2509424A4 (es)
JP (1) JP2013512951A (es)
CN (1) CN102762102A (es)
AR (1) AR077908A1 (es)
CA (1) CA2783851A1 (es)
MX (1) MX2012006667A (es)
TW (1) TW201120016A (es)
UY (1) UY32853A (es)
WO (1) WO2011071570A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2947080B1 (en) 2007-08-13 2017-10-25 Monsanto Technology LLC Compositions and methods for controlling nematodes
US8729109B2 (en) 2011-09-08 2014-05-20 Allergan, Inc. 3-(4-(5-phenyl-1 ,2,4-oxadiazol-3-yl)phenoxy)propan-2-ol derivatives as sphingosine-1phosphate receptors modulators
PT2970236T (pt) 2013-03-15 2017-11-30 Idorsia Pharmaceuticals Ltd Derivados de piridin-4-ilo
JP6615876B2 (ja) * 2014-06-26 2019-12-04 モナシュ ユニヴァーシティ 酵素相互作用薬剤
US20220041572A1 (en) * 2018-09-18 2022-02-10 Bristol-Myers Squibb Company Cycloheptyl acids as lpa antagonists
WO2020060915A1 (en) * 2018-09-18 2020-03-26 Bristol-Myers Squibb Company Cyclopentyl acids as lpa antagonists
CN109369620B (zh) * 2018-12-22 2020-04-14 山东大学 吡啶类化合物及其制备方法与抗胃癌应用
CN109776443B (zh) * 2019-03-25 2022-09-27 上海万巷制药有限公司 一种具有抗氧化作用的噁二唑类化合物及其制备方法
US20230067910A1 (en) 2019-11-19 2023-03-02 Modag Gmbh Novel compounds for the diagnosis, treatment and prevention of diseases associated with the aggregation of alpha-synuclein
UY38964A (es) 2019-11-25 2021-06-30 Novartis Ag Derivados de 1,2,4-oxadiazol como agonistas del receptor hepático x, sus usos y métodos relacionados referencia cruzada a solicitudes relacionadas
CN115260173B (zh) * 2021-04-30 2024-08-30 厦门宝太生物科技股份有限公司 环戊烷并吲哚类支链酸衍生物及其制备方法和应用
CN113662938B (zh) * 2021-09-26 2022-08-16 广西科技大学 一种胺类衍生物在制备抗肿瘤药物组合物中的应用
WO2023118253A1 (en) * 2021-12-23 2023-06-29 Chiesi Farmaceutici S.P.A. Cyclohexane acid derivatives as lpa receptor inhibitors
WO2024151993A1 (en) * 2023-01-13 2024-07-18 Oppilan Pharma Limited Preparation of an s1p receptor modulator
CN116444454B (zh) * 2023-06-16 2023-09-12 中国医学科学院医药生物技术研究所 N-羟基脒衍生物及制备方法和应用、肿瘤免疫治疗药物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007080542A1 (en) * 2006-01-11 2007-07-19 Actelion Pharmaceuticals Ltd Novel thiophene derivatives as s1p1/edg1 receptor agonists
WO2008029370A1 (en) * 2006-09-08 2008-03-13 Actelion Pharmaceuticals Ltd Pyridin-3-yl derivatives as immunomodulating agents
WO2009109904A1 (en) * 2008-03-07 2009-09-11 Actelion Pharmaceuticals Ltd Novel aminomethyl benzene derivatives
WO2010148650A1 (en) * 2009-06-26 2010-12-29 Glaxo Group Limited 5-membered heteroaryl derivatives used as sphingosine 1-phosphate receptor agonists

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101490046A (zh) * 2006-05-09 2009-07-22 辉瑞产品公司 环烷基氨基酸衍生物及其药物组合物
BRPI0720043A2 (pt) * 2006-12-15 2014-01-07 Abbott Lab Composto oxadiazol

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007080542A1 (en) * 2006-01-11 2007-07-19 Actelion Pharmaceuticals Ltd Novel thiophene derivatives as s1p1/edg1 receptor agonists
WO2008029370A1 (en) * 2006-09-08 2008-03-13 Actelion Pharmaceuticals Ltd Pyridin-3-yl derivatives as immunomodulating agents
WO2009109904A1 (en) * 2008-03-07 2009-09-11 Actelion Pharmaceuticals Ltd Novel aminomethyl benzene derivatives
WO2010148650A1 (en) * 2009-06-26 2010-12-29 Glaxo Group Limited 5-membered heteroaryl derivatives used as sphingosine 1-phosphate receptor agonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2011071570A1 *

Also Published As

Publication number Publication date
UY32853A (es) 2011-06-30
CN102762102A (zh) 2012-10-31
CA2783851A1 (en) 2011-06-16
MX2012006667A (es) 2012-10-15
TW201120016A (en) 2011-06-16
AR077908A1 (es) 2011-09-28
EP2509424A1 (en) 2012-10-17
WO2011071570A1 (en) 2011-06-16
JP2013512951A (ja) 2013-04-18

Similar Documents

Publication Publication Date Title
GB0919423D0 (en) Novel compounds
EP2483254A4 (en) NEW COMPOUNDS
GB0905955D0 (en) Novel compounds
EP2509424A4 (en) NOVEL OXADIAZOLE COMPOUNDS
EP2512242A4 (en) NEW COMPOUNDS
GB0910674D0 (en) Novel compounds
GB0910691D0 (en) Novel compounds
GB0911130D0 (en) Novel compounds
GB0910689D0 (en) Novel compounds
GB0910009D0 (en) Novel compounds
GB0910688D0 (en) Novel compounds
GB0907118D0 (en) Novel compounds
GB0907820D0 (en) Novel compounds
GB0906577D0 (en) Novel compounds
GB0906578D0 (en) Novel compounds
GB0907104D0 (en) Novel compounds
GB0907105D0 (en) Novel compounds
GB0907106D0 (en) Novel compounds
GB0907107D0 (en) Novel compounds
GB0907112D0 (en) Novel compounds
GB0907113D0 (en) Novel compounds
GB0907114D0 (en) Novel compounds
GB0907116D0 (en) Novel compounds
GB0907117D0 (en) Novel compounds
GB0906288D0 (en) Novel compounds

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20120703

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME RS

A4 Supplementary search report drawn up and despatched

Effective date: 20130802

RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 487/04 20060101ALI20130729BHEP

Ipc: A61K 31/41 20060101ALI20130729BHEP

Ipc: C07D 471/04 20060101ALI20130729BHEP

Ipc: A01N 43/82 20060101AFI20130729BHEP

Ipc: C07D 413/12 20060101ALI20130729BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20140301